Tema ETFs LLC Buys Shares of 29,519 Tyra Biosciences, Inc. $TYRA

Tema ETFs LLC purchased a new stake in shares of Tyra Biosciences, Inc. (NASDAQ:TYRA) during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 29,519 shares of the company’s stock, valued at approximately $943,000.

Several other large investors also recently modified their holdings of the company. Hilton Head Capital Partners LLC bought a new position in Tyra Biosciences in the first quarter valued at about $30,000. Caitong International Asset Management Co. Ltd bought a new stake in shares of Tyra Biosciences during the 4th quarter valued at about $51,000. Chung Wu Investment Group LLC purchased a new stake in shares of Tyra Biosciences during the 4th quarter valued at about $53,000. Mirae Asset Global Investments Co. Ltd. increased its position in shares of Tyra Biosciences by 25.9% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,594 shares of the company’s stock valued at $68,000 after purchasing an additional 534 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in shares of Tyra Biosciences by 14.5% in the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 13,182 shares of the company’s stock worth $126,000 after purchasing an additional 1,668 shares during the period. Institutional investors own 84.14% of the company’s stock.

Analyst Ratings Changes

TYRA has been the topic of a number of research reports. Bank of America raised their price objective on shares of Tyra Biosciences from $37.00 to $42.00 and gave the stock a “buy” rating in a report on Wednesday, June 10th. JonesTrading started coverage on shares of Tyra Biosciences in a report on Wednesday, June 17th. They set a “buy” rating and a $56.00 target price for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Tyra Biosciences in a research report on Friday, July 17th. HC Wainwright reiterated a “buy” rating and set a $45.00 price target on shares of Tyra Biosciences in a research note on Thursday, May 14th. Finally, Jefferies Financial Group reissued a “buy” rating and set a $42.00 price objective on shares of Tyra Biosciences in a research report on Wednesday, August 5th. One research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $46.90.

Tyra Biosciences Stock Down 1.1%

Shares of Tyra Biosciences stock opened at $25.02 on Friday. The stock’s 50-day simple moving average is $29.78 and its 200-day simple moving average is $32.56. Tyra Biosciences, Inc. has a 52 week low of $9.96 and a 52 week high of $40.65. The company has a market capitalization of $1.49 billion, a price-to-earnings ratio of -10.43 and a beta of 0.77.

Tyra Biosciences (NASDAQ:TYRA) last announced its quarterly earnings data on Tuesday, August 4th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.04). On average, equities analysts expect that Tyra Biosciences, Inc. will post -2.74 earnings per share for the current year.

About Tyra Biosciences

Tyra Biosciences (NASDAQ: TYRA) is a clinical-stage precision oncology company focused on the discovery and development of small-molecule therapies for genetically defined cancers. The company integrates bioinformatics, molecular biology and medicinal chemistry to identify oncogenic drivers and design targeted inhibitors. By leveraging large-scale genomic datasets and functional screening, Tyra Biosciences aims to advance therapies that address patient populations with high unmet medical need.

The company’s pipeline includes multiple programs at various stages of development, each directed against distinct molecular vulnerabilities in cancer cells.